Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Nautilus Biotechnology Q4 EPS $(0.13), Inline

Nautilus Biotechnology (NASDAQ:NAUT) reported quarterly losses of $(0.13) per share which met the analyst consensus estimate.

byBenzinga Newsdesk

February 24, 2022

1 minute read

Nautilus Biotechnology (NASDAQ:NAUT) reported quarterly losses of $(0.13) per share which met the analyst consensus estimate.

Medical Properties Trust: Q1 Earnings Insights

By Benzinga Insights

Today, 10:17 PM

Medical Properties Trust (NYSE:MPW) reported its Q1 earnings results on Thursday, April 28, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

MPW

Truist Securities Downgrades Renewable Energy Gr to Hold

By Benzinga Newsdesk

Today, 10:17 PM

Truist Securities analyst Jordan Levy downgrades Renewable Energy Gr (NASDAQ:REGI) from Buy to Hold.

REGI

Galmed Pharmaceuticals Q2 EPS $(0.33) Beats $(0.38) Estimate

By Bill Haddad

Today, 10:17 PM

Galmed Pharmaceuticals (NASDAQ:GLMD) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.38) by 13.16 percent. This is a 26.92 percent decrease over losses of $(0.26) per share

GLMD